419 related articles for article (PubMed ID: 31865475)
1. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
3. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
Li Q; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R; Xu B
Cancer Biol Ther; 2015; 16(12):1746-53. PubMed ID: 26466918
[TBL] [Abstract][Full Text] [Related]
6. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
[TBL] [Abstract][Full Text] [Related]
7. Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Asleh K; Brauer HA; Sullivan A; Lauttia S; Lindman H; Nielsen TO; Joensuu H; Thompson EA; Chumsri S
Clin Cancer Res; 2020 Jun; 26(11):2603-2614. PubMed ID: 32005747
[TBL] [Abstract][Full Text] [Related]
8. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
Natori A; Ethier JL; Amir E; Cescon DW
Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
Li Q; Xu B; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R
Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):938-41. PubMed ID: 26887625
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
[TBL] [Abstract][Full Text] [Related]
12. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
13. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
[TBL] [Abstract][Full Text] [Related]
14. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Taşçı EŞ; Kutlu Y; Ölmez ÖF; Mutlu AU; Gündoğdu Y; Seyyar M; Şahin E; Çabuk D; Majidova N; Uğurlu İ; Demirci A; Aydın D; Çavdar E; Bayram S; Yıldırım N; Karataş F; Eryılmaz MK; Çağlayan D; Menekşe S; Kut E; Arak H; Keser M; Sunar V; Perkin P; Şakalar T; Oyan B; Sönmez Ö; Özer L; Yıldız İ
Expert Opin Pharmacother; 2024 Mar; 25(4):477-484. PubMed ID: 38568074
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Lee J; Kim HH; Ro SM; Yang JH
PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis.
Petrelli F; Bertaglia V; Parati MC; Borgonovo K; De Silva P; Luciani A; Novello S; Scartozzi M; Emens LA; Solinas C
Breast; 2023 Feb; 67():8-13. PubMed ID: 36549170
[TBL] [Abstract][Full Text] [Related]
19. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
Rugo HS; Roche H; Thomas E; Chung HC; Lerzo GL; Vasyutin I; Patel A; Vahdat L
Clin Breast Cancer; 2018 Dec; 18(6):489-497. PubMed ID: 30153978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
